One deal towers above the rest in our look at the $1.41 billion private capital activity in healthcare for the week of Nov. 16-20.
After operating as the venture capital arm of UK pharmaceutical giant GlaxoSmithKline (GSK) since 1985, SR One cemented its spinoff status by closing its first independent fund.
Oversubscribed at $500 million, the fund was cobbled together with support from a "pool of global institutional asset managers, endowments, foundations, pension funds and family offices," according to SR One. GSK made the largest investment in the fund, but the other players . . .
Unlock this article instantly, along with the rest of our premium content and daily, weekly and monthly newsletters. We offer pay-as-you-go monthly subscriptions and discounted annual subscriptions with additional benefits: access to Alternatives Watch Research articles and our Annual Investor Compendium.